Serial No.: N/A

Art Unit N/A

Preliminary Amendment prior to Examination

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.(Currently Amended) Process for preparing emtricitabine of formula

HO
$$\frac{2R}{5S}$$
 $\frac{N}{5S}$ NH₂

which comprises the salification reaction of the intermediate compound of formula

$$\begin{array}{c|c}
\hline
5^{\circ}R & O & O \\
2^{\circ}S & = 1^{\circ}R & O & 2R \\
\hline
5^{\circ}S & 5^{\circ}S
\end{array}$$

$$F \qquad (XIa)$$

dissolved in a suitable solvent, by treatment with <u>an</u> organic or mineral [[acids]] <u>acid</u> to give the corresponding salt.

- 2.(Currently Amended) Process according to The process of Claim 1, characterized in that the intermediate compound of formula XIa is dissolved in a suitable solvent by treatment with organic or mineral acids to give wherein the corresponding salt is in readily isolable solid form.
- 3.(Currently Amended) The process of Process according to Claim 1, characterized in that wherein the solvent is chosen selected from the group consisting of alcohols, hydrocarbons, esters, ethers, [[and]] chlorinated solvents, [[or]] and mixtures thereof.

Serial No.: N/A

Art Unit N/A

Preliminary Amendment prior to Examination

The process of Process according to Claim 3, characterized in 4.(Currently Amended) that-wherein the solvent is chosen selected from the group consisting of methanol, ethanol, isopropanol, toluene, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, tetrahydrofuran, dioxane, [[and]] methylene chloride, [[or]] and mixtures thereof [[, preferably from methanol, isopropanol and ethyl acetate, or mixtures thereof]].

- The process of Process according to Claim 1, characterized in 5.(Currently Amended) that the wherein said organic or mineral acid is [[chosen]] selected from the group consisting of fumaric acid, maleic acid, lactic acid, salicylic acid, succinic acid, glycolic acid, tartaric acid, acetic acid, citric acid, formic acid, benzoic acid, malonic acid, oxalic acid, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, perchloric acid, phosphoric acid, p-toluenesulphonic acid, methanesulphonic acid, 2-naphthalenesulphonic acid, benzenesulphonic acid, [[and]] 4-chlorobenzenesulphonic acid, and mixtures thereof.
- 6.(Currently Amended) The process of Process according to Claim 5, characterized in that the wherein said organic or mineral acid is [[chosen]] selected from the group consisting of oxalic acid, succinic acid, maleic acid, methanesulphonic acid, 4chlorobenzene-sulphonic acid, [[and]] hydrochloric acid, and mixtures thereof [[and is preferably oxalic acid]].
- The process of Process according to Claim 1, further 7.(Currently Amended) comprising isolating [[characterized in that the]] said corresponding salt [[is isolated]] by filtration.

Serial No.: N/A

+ Unit N/Δ

Preliminary Amendment prior to Examination

8.(Currently Amended) The process of Process according to Claim 1, which further comprises the condensation reaction between condensing 5-fluorocytosine of formula (III)

in suitably activated form, and the compound of formula (VI)

$$2'S \longrightarrow 1'R \longrightarrow 0$$

$$1'R \longrightarrow 2R \longrightarrow 0$$

$$(VI)$$

in which LG represents a leaving group [[chosen]] selected from the group consisting of [[from]] acetate, halo, cyano, [[optionally]] halogenated alkylsulphonate, [[alkylsulphonates, or]] arylsulphonate arylsulphonates, and mixtures thereof, to give the compound of formula XIa.

- 9. (Currently Amended) The process of Process according to Claim 8, in which LG represents a leaving group chosen from selected from the group consisting of acetate, chloro, bromo, iodo, methanesulphonate, triflate, tosylate, [[and]] benzenesulphonate, and mixtures thereof [[and preferably from chloro and acetate]].
- 10. (Currently Amended) The process of claim 1, further comprising reducing Process

 according to Claim 1 or 8, which further comprises the reduction reaction of compound

 Xla to give emtricitabine (Ia).

Serial No.: N/A

Art Unit N/A

Preliminary Amendment prior to Examination

11. (Original) Process according to Claim 10, characterized in that the said reduction reaction is performed by releasing in situ the base of compound XIa from its isolated salt via a basic treatment.

- 12. (Canceled)
- 13.(Original) Process for preparing the compound of formula

which comprises the salification reaction of the intermediate compound of formula

$$2'R$$
 $1'S'' \circ 2S$
 $5'R$
 NH_2
 F
(XId)

dissolved in a suitable solvent, by treatment with organic or mineral acids to give the corresponding salt, which is insoluble in the said solvent, in readily isolable solid form.

- 14.(New) The process of Claim 3, wherein the solvent is from the group consisting of methanol, isopropanol, ethyl acetate, and mixtures thereof.
- 15.(New) The process of Claim 8, in which LG represents a leaving group selected from the group consisting of chloro, acetate, and mixtures thereof.

Attorney's Docket: 2003IT301
Serial No.: N/A
Art Unit N/A
Preliminary Amendment prior to Examination

16.(New)

The process of Claim 5, wherein said organic or mineral acid is

oxalic acid.

Serial No.: N/A

Art Unit N/A

Preliminary Amendment prior to Examination

REMARKS

Applicant has amended the claims to attend to housekeeping and to place the

Application in proper form for examination. Applicant amended the Specification to correct an

obvious typographical error which was not earlier noticed. An Abstract of the Disclosure is

now provided. Support for the Abstract can be found in Applicant's Specification in

paragraphs [001] and [002], and originally filed claim 1. It is believed that no new matter was

introduced by this amendment.

Claims 1-12 were amended to attend to formal matters. Support for amended claims

1-12 may be found in originally filed claims 1-13. Support for new claims 14-16 may be found

in original claims 4, 6, and 9. It is believed that no new matter has been introduced by these

amendments. Claim 12 was canceled.

An early and favorable action on the merits is respectfully requested. The

Commissioner is hereby authorized to charge any fee deficiency to Deposit Account No. 03-

2060.

Respectfully submitted,

Richard P. Silverman, Reg. No. 36,277

(CUSTOMER NUMBER 25,255)

CLARIANT CORPORATION INDUSTRIAL PROPERTY DEPARTMENT 4000 Monroe Road

Charlotte, NC 28205

Phone

(704) 331-7156 (704) 331-7707 Fax